Maroni Paola, Matteucci Emanuela, Bendinelli Paola, Desiderio Maria Alfonsina
Galeazzi Orthopaedic Institute, Scientific Institute for Research, Hospitalization and Health Care (IRCCS), 20161 Milano, Italy.
Department of Biomedical Sciences for Health, Molecular Pathology Laboratory, Università degli Studi di Milano, 20133 Milano, Italy.
Int J Mol Sci. 2017 Jan 1;18(1):75. doi: 10.3390/ijms18010075.
Epigenetic mechanisms influence molecular patterns important for the bone-metastatic process, and here we highlight the role of WW-domain containing oxidoreductase (Wwox). The tumor-suppressor Wwox lacks in almost all cancer types; the variable expression in osteosarcomas is related to lung-metastasis formation, and exogenous Wwox destabilizes HIF-1α (subunit of Hypoxia inducible Factor-1, HIF-1) affecting aerobic glycolysis. Our recent studies show critical functions of Wwox present in 1833-osteotropic clone, in the corresponding xenograft model, and in human bone metastasis from breast carcinoma. In hypoxic-bone metastatic cells, Wwox enhances HIF-1α stabilization, phosphorylation, and nuclear translocation. Consistently, in bone-metastasis specimens Wwox localizes in cytosolic/perinuclear area, while TAZ (transcriptional co-activator with PDZ-binding motif) and HIF-1α co-localize in nuclei, playing specific regulatory mechanisms: TAZ is a co-factor of HIF-1, and Wwox regulates HIF-1 activity by controlling HIF-1α. In vitro, DNA methylation affects Wwox-protein synthesis; hypoxia decreases Wwox-protein level; hepatocyte growth factor (HGF) phosphorylates Wwox driving its nuclear shuttle, and counteracting a Twist program important for the epithelial phenotype and metastasis colonization. In agreement, in 1833-xenograft mice under DNA-methyltransferase blockade with decitabine, Wwox increases in nuclei/cytosol counteracting bone metastasis with prolongation of the survival. However, Wwox seems relevant for the autophagic process which sustains metastasis, enhancing more Beclin-1 than p62 protein levels, and p62 accumulates under decitabine consistent with adaptability of metastasis to therapy. In conclusion, Wwox methylation as a bone-metastasis therapeutic target would depend on autophagy conditions, and epigenetic mechanisms regulating Wwox may influence the phenotype of bone metastasis.
表观遗传机制影响着对骨转移过程至关重要的分子模式,在此我们重点介绍含WW结构域的氧化还原酶(Wwox)的作用。肿瘤抑制因子Wwox在几乎所有癌症类型中都缺失;骨肉瘤中的可变表达与肺转移形成有关,外源性Wwox会使缺氧诱导因子-1α(缺氧诱导因子-1,HIF-1的亚基)不稳定,影响有氧糖酵解。我们最近的研究表明,Wwox在1833向骨趋化克隆、相应的异种移植模型以及乳腺癌的人骨转移中发挥关键作用。在缺氧的骨转移细胞中,Wwox增强HIF-1α的稳定性、磷酸化和核转位。一致的是,在骨转移标本中,Wwox定位于胞质/核周区域,而TAZ(具有PDZ结合基序的转录共激活因子)和HIF-1α共定位于细胞核中,发挥特定的调控机制:TAZ是HIF-1的辅因子,Wwox通过控制HIF-1α来调节HIF-1活性。在体外,DNA甲基化影响Wwox蛋白的合成;缺氧降低Wwox蛋白水平;肝细胞生长因子(HGF)使Wwox磷酸化,驱动其核穿梭,并对抗对上皮表型和转移定植重要的Twist程序。同样,在用地西他滨阻断DNA甲基转移酶的1833异种移植小鼠中,Wwox在细胞核/细胞质中增加,通过延长生存期来对抗骨转移。然而,Wwox似乎与维持转移的自噬过程相关,增强Beclin-1的水平多于p62蛋白水平,并且在地西他滨作用下p62积累,这与转移对治疗的适应性一致。总之,Wwox甲基化作为骨转移治疗靶点将取决于自噬条件,调节Wwox的表观遗传机制可能会影响骨转移的表型。